Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Despite a trend moving toward lower doses of radiotherapy, higher doses may confer a survival benefit.
A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.
Survival benefits were maintained among those with brain metastases.
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
Lurbinectedin is a selective inhibitor of trans-activated RNA polymerase II transcription.
However, incontinence and sexual function are worse five years following prostatectomy.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
A study found that young women in the United States had a higher incidence of lung cancer that could not be explained by known risk factors, such as smoking.
Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.
Medical and ethical considerations are discussed, including in cases of conflict between parent, child.
Burden varies across states, with highest burden seen in Hawaii.
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.